Associação Brasileira do Tumor Desmóide

O Desmoid Tumor Research Foundation - a fundação que financia estudos específicos para desmóide nos EUA realiza um simpósio anualmente em setembro, especificamente para médicos, para apresentar as últimas descobertas a cerca desse tumor. Este ano não será…

Lembram desse simpósio que a DTRF está promovendo especificamente para os médicos?
Vejam só a programação (mais uma vez frizo a importância de estimularmos nossos médicos a participarem desse tipo de evento para que saibam cada vez mais sobre as mais novas abordagens e descobertas acerca desse tumor danado):

Event speakers and their topics are listed below:

Welcome: Jeanne Whiting, President and Co-Founder, DTRF.

Benjamin Alman, MD, Professor & Chair, Orthopaedic Surgery, Duke University, and Maneesh Kumar, MD, PhD, Research Director, DTRF Coordinating Center, Welcome/DTRF Updates.

Yoshihiro Nishida, MD, Rehabilitation & Orthopedic Oncology, Nagoya University Graduate School of Medicine, “Diagnostic and therapeutic strategies for extra-abdominal desmoid-type fibromatosis: a longitudinal questionnaire survey to specialized centers in Japan.”

Hyo Song Kim, MD, Department of Internal Medicine, Yonsei University, “Genomic and transcriptomic analysis of desmoid tumor reveals enrichment of transforming growth factor beta responsive signature.”

Afshin Gangi, MD, PhD, Strasbourg’s University Hospitals, “Evaluation of the Cryodestruction of Non- Abdominopelvic Desmoid Tumors in Patients Progressing despite Medical Treatment (CRYODESMO01).”

Nicholas Penel, MD, PhD, Director of Clinical Research & Innovation Dept/ Head of General Oncology in Medical Oncology, Oscar Lambret Cancer Centre. “Prognosis value of S45F mutation of CTNNB1 in desmoid-type fibromatosis (DF). Prospective analysis of 500 consecutive patients (pts) from ALTITUDES Trial.”

Sara Coppola, MD, Sarcoma Department, IEO Istituto Europeo di Oncologia, “Abdominal Desmoid Tumors: A series from a single institution.”

Ed Neilan, MD, PhD, Chief Medical Officer, NORD, “Data sharing and RDCA-DAP.”

KEYNOTE: Stefani Spranger, PhD, Assistant Professor of Biology, Massachusetts Institute of Technology, “Not all anti-tumor T cell responses are created equal.”

Kris Vleminckx, PhD, Professor of Developmental Biology, Ghent University, “Investigating the mechanisms and tumor-host interactions mediating desmoid tumor regression by EZH2 inhibition in CRISPR-based Xenopus tropicalis models.”

Gerlinde Wernig, MD, Assistant Professor, and Cristabelle De Souza, MD, Postdoctoral Fellow, Department of Pathology, Stanford University, “Evaluating CD47 blockade as a potential immunotherapy for desmoid-type fibromatosis.”

Mushriq Al-Jazrawe, PhD, Post-doctoral Associate, The Broad Institute of MIT and Harvard, “Developing a physiologically relevant target validation platform for desmoid tumors.”

Daniela Segat, PhD, Researcher, “Mauro Baschirotto” Institute for Rare Diseases – BIRD Foundation, “CRISPR/Cas9 approach for creating a simplified cellular model to study the Desmoid cells in response to external stimuli and in cellular communication.”

Ludmilla Thome Domingos Chinen, PhD, Senior researcher, Pesquisadora Hospital ACCamargo- Fundação Antônio Prudente, “Circulating tumor cells in desmoid tumors.”

Sameer Rastogi, MD, Associate Professor, Dept. of Medical Oncology, All India Institute of Medical Sciences (AIIMS), New Delhi, “Patient-reported outcomes in patients with desmoid type fibromatosis.”

Sukanya Subramanian, MD, Transplant Gastroenterologist, Medstar Georgetown University Hospital, “Intestinal transplant as rescue therapy.”

Amanda Hoffman, Desmoid Patient Advocate

Gary Gordon, MD, PhD, Chief Medical Officer, and Jason Kaplan, MD, Medical Director, Ayala Pharmaceuticals, “AL102, Investigational Oral Gamma-Secretase Inhibitor for the Potential Treatment of Desmoid Tumors.”

Jessica White, PhD student, SpringWorks Therapeutics, Inc., “The Epidemiology of Desmoid Tumors in Denmark.”

Anne-Rose Schut, MD, PhD candidate, Surgical Oncology and Medical Oncology, Erasmus Medical Center Cancer Institute, “The evaluation of health-related quality of life issues experienced by patients with desmoid-type fibromatosis (The QUALIFIED STUDY).”

28 views19:50